Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

On July 14, 2026, Can-Fite BioPharma Ltd., a biotechnology company, revealed that the Australian Patent Office has approved Patent Application No. 2021290439 named "Treatment of Advanced Metastatic Cancer.” Can-Fite BioPharma is listed on the NYSE American as CANF and on the TASE as CANF. The company focuses on developing small molecule drugs for oncological and inflammatory conditions. This patent approval signifies a milestone in their efforts to create treatments for advanced metastatic cancer.